T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Publisher: La Merie Publishing
Pages: 230
Format: PDF
Product Line:
LMP Full Report
Product Code: LMFR0018
Release Date: May of 2016

2,050.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

T-Cell Redirecting Bispecific Antibodies 2016:
A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR). Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on this field of adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.

Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development. Within 18 months, the number of clinical stage T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months.

This report „T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals“ as of May 2016 brings you up-to-date information about and analysis of 34 corporate players, 22 key technologies, 47 T-cell and NK-cell redirecting bispecific antibody profiles, business deals and private and public financing rounds.

The report analyzes the pipeline of T-cell and NK-cell redirecting bispecific antibody molecules regarding preferred targets, molecular constructs, dosing schedules, clinical experience, combination study plans, competition with other treatment modalities and the next wave of T-cell and NK-cell redirecting antibodies.
Preferences in bispecific antibody technologies are evaluated regarding drug candidate output, partnering, technological features and impact on clinical administration regimens.

The report highlights the commercial value of T-cell redirecting bispecific antibody immunotherautics in terms of drug prices, sales, company acquisition prices, economic terms of partnering deals, and private or public financing rounds.

Download Samples Pages: T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

All information in the report is fully referenced with 159 scientific references, in many cases with hyperlinks leading to the source of information (abstracts, Posters, papers). Non-scientific references, such as press releases, annual reports or company presentations are disclosed within the text with an embedded hyperlink leading to the online source of information.

What will you find in the report?

  • Profiles of 34 companies active in the field;
  • Comprehensive description of 23 established and emerging T-cell or NK-cell redirecting antibodies
  • Profiles of two approved and 45 T-cell or NK-cell redirecting bispecific antibodies in all phases of development;
  • Technology selection and preferences of major pharma;
  • Key characteristics of technologies with clinical stage drug candidates
  • Emerging alternative bi- and trispecific formats
  • Target selection and competition in drug candiates
  • Competition of recombinant bispecific molecules with alternative treatment modalities
  • Dosing schedules of clinical stage drug candidates based on molecular features
  • Economic terms of collaboration and licensing deals;

Who will benefit from the report?

  • Venture capital, private equity and investment managers;
  • Financial analysts;
  • CFO;
  • Business development and licensing (BDL) specialists;
  • Marketing managers;
  • CEO, COO and managing directors;
  • Corporate strategy, product and portfolio analysts and managers;
  • Chief Technology Officer;
  • Cell technology and manufacturing specialists;
  • Clinical and preclinical development specialists.

 

 

T-Cell Redirecting Bispecific Antibodies 2016:

A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Table of Contents


1          Introduction

2          Executive Summary

3          Competitive Landscape Analysis

3.1       Stakeholders

3.1.1    Major biopharmaceutical companies
3.2.2    Small & medium pharmaceutical & biotechology companies

3.2       Technologies

3.3       Pipeline
3.3.1    Overview
3.3.2    Targets
3.3.3    Competition with other Treatment Modalities
3.3.4    Administration Regimens of T-cell Redirecting Bispecific Antibodies
3.3.5    Next Wave of T-cell and NK-Cell Redirecting Antibodies
3.3.6    Clincial Experience with T-cell and NK-cell redirecting Bispecific Antibodies

3.4       Commercial value of targets, drugs & technologies
3.4.1    Drug prices and sales
3.4.2    Economic terms of collaboration and licensing agreements
3.4.3    Acquisition price (cost) of companies
3.4.4    Public and private financing rounds

4.         Company Profiles

4.1       Major Pharma & Biotech
4.1.1    Amgen
4.1.2    AstraZeneca
4.1.3    Bayer
4.1.4    Boehringer Ingelheim
4.1.5    Eli Lilly
4.1.6    GlaxoSmithKline
4.1.7    Janssen Biotech
4.1.8    Pfizer
4.1.9    Roche
4.1.10  Servier

4.2       Small & Medium Pharma & Biotech
4.2.1    Adimab
4.2.2    Affimed Therapeutics
4.2.3    Alligator Biosciences
4.2.4    Ambrx
4.2.5    CytomX
4.2.6    Emergent BioSolutions
4.2.7    EngMab
4.2.8    Eureka Therapeutics
4.2.9    GEMoaB
4.2.10  Generon
4.2.11  Genmab
4.2.12  Glenmark Pharmaceuticals
4.2.13  Immunocore
4.2.14  MacroGenics
4.2.15  Merus
4.2.16  Molecular Partners
4.2.17  Morphosys
4.2.18  Neovii Biotech
4.2.19  OMT Therapeutics
4.2.20  Pieris
4.2.21  Regeneron Pharmaceuticals
4.2.22  Wuhan YZY Biopharma
4.2.23  Xencor
4.2.24  Zymeworks

5          Technology Profiles

5.1       ADAPTIR
5.2       ART-Ig
5.3       Azymetric Scaffold
5.4       BEAT
5.5       Biclonics
5.6       BiTE
5.7       CrossMab
5.8       DART
5.9       Fc-DART
5.10     Dock-and-Lock (DNL)
5.11     DuoBody
5.12     FynomAbs
5.13     ImmTAC
5.14     Knobs-into-Holes
5.15     mAbXcite
5.16     Modified VelocImmune
5.17     TandAb
5.18     T-Cell Engaging Bi-specific (TCB) Probody
5.19     Triomab
5.20     UniDab
5.21     UniTARG / UniMAB
5.22     XmAb Bispecific
5.23     Y-Body Bispecific

6          Drug & Drug Candidate Profiles

6.1       A-337
6.2       AFM11
6.3       AFM13
6.4       AFM21
6.5       AFM22
6.6       AFM24
6.7       AMG 221
6.8       AMG 330
6.9       AMV-564
6.10     BI 836909
6.11     Bispecific anti-CD3-folate
6.12     Blincyto
6.13     CD79b-TDB
6.14     COVA420
6.15     DR5xCD3 DART
6.16     EM801
6.17     EphA2xCD3 DART
6.18     ERY974
6.19     ES414
6.20     ES425
6.21     GBR1302
6.22     GBR1342
6.23     Her2-TDB
6.24     IL13Rα DART
6.25     IMCgp100
6.26     JNJ-63709178
6.27     JNJ-64052781
6.28     M-706
6.29     M-802
6.30     MCLA-117
6.31     MGD006
6.32     MGD007
6.33     MGD009
6.34     MGD014
6.35     Pasotuxizumab
6.36     PF-06671008
6.37     PRS-343
6.38     PSMA-CD3
6.39     REGN1979
6.40     Removab
6.41     RG7802
6.42     RG7828
6.43     ROR1xCD3 DART
6.44     XmAb13551
6.45     XmAb13676
6.46     XmAb14045
6.47     ZW38

7          References

8          Attachment

  • Table 16: Clinical Stage T-Cell and NK-Cell Redirecting Bispecific Antibodies
  • Table 17: Clinical Combination Studies with T-Cell and NK-Cell Redirecting Bispecific Antibodies
  • Table 18: T-Cell and NK-Cell Redirecting Bispecific Antibodies in IND and IND-Enabling Study Phase
  • Table 19: T-Cell and NK-Cell Redirecting Bispecific Antibodies in Preclinical R&D


T-Cell Redirecting Bispecific Antibodies 2016:
A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Tables in the Report

Table 1: Technologies Used by Big Pharma / Biotech in Clinical Stage T-Cell Redirecting Bispecific Antibodies and Compared with Related Technologies
Table 2: T-Cell & NK-Cell Redirecting Bispecific Antibody Technologies from Small & Medium Pharmaceutical Companies and their Licensees
Table 3: Technology Features of Clinical Stage T-Cell & NK-Cell Redirecting Bispecific Antibody Technologies
Table 4: Corporate T-Cell and NK-Cell Redirecting Bispecific Antibody Technologies
Table 5: Targets for T-Cell & NK-Cell Redirecting Bispecific Antibodies
Table 6: Target Competition by Treatment Modalities
Table 7: Technology-Dependent Administration Regimens of Clinical Stage T-Cell & NK-Cell Redirecting Bispecific Antibodies
Table 8: Next Wave of T-Cell and NK-Cell Redirecting Bispecific Antibodies
Table 9: Economic Terms of Licensing Agreements for T-Cell Redirecting Bispecific Antibodies
Table 10: Clinical Development Indications and Status of Blincyto
Table 11: BiTE Development Pipeline by Amgen and/or Partners
Table 12: Affimed’s TandAb Pipeline
Table 13: Goals and Terms of Immunocore’s Partnering Deals for ImmTAC Technology
Table 14: YZY Biopharma‘s Pipeline of T-Cell Redirecting Bispecific Antibodies
Table 15: Clinical Studies with Blincyto (blinatumomab)
Table 16: Clinical Stage T-Cell and NK-Cell Redirecting Bispecific Antibodies
Table 17: Clinical Combination Studies with T-Cell and NK-Cell Redirecting Bispecific Antibodies
Table 18: T-Cell and NK-Cell Redirecting Bispecific Antibodies in IND and IND-Enabling Study Phase
Table 19: T-Cell and NK-Cell Redirecting Bispecific Antibodies in Preclinical R&D

 


T-Cell Redirecting Bispecific Antibodies 2016:
A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Companies mentioned in the report

Adimab
Affimed Therapeutics
Alligator Biosciences
Ambrx
Amgen
AstraZeneca
Bayer
Boehringer Ingelheim
CytomX
Eli Lilly
Emergent BioSolutions
EngMab
Eureka Therapeutics
GEMoaB
Generon
Genmab
GlaxoSmithKline
Glenmark Pharmaceuticals
ImmuneXcite
Immunocore
Immunomedics
Janssen Biotech
MacroGenics
Merus
Molecular Partners
Morphosys
Neovii Biotech
OMT Therapeutics
Pfizer
Pieris Pharmaceuticals
Regeneron Pharmaceuticals
Roche
Servier
Wuhan YZY Biopharma
Xencor
Zymeworks



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top